GENE ONLINE|News &
Opinion
Blog

2018-10-02| Technology

Cancer immunotherapy researchers earn prestigious Nobel for 2018

by Rajaneesh K. Gopinath
Share To

This year’s prize in Physiology or Medicine honors the discovery of cancer therapy by inhibition of negative immune regulation

By Rajaneesh K Gopinath

The Nobel Assembly at the Karolinska Institutet announced yesterday about their decision to jointly award James Allison, PhD, and Tasuku Honjo, MD, PhD for their separate pioneering works in “immune checkpoint” cancer therapy. Dr. Allison, also the recipient of the 2015 Lasker award is currently the chair of the department of immunology at the University of Texas MD Anderson Cancer Center in Houston while Dr. Honjo is a professor of immunology and genomic medicine at Kyoto University in Japan.

Although the utilization of our body’s own immune cells to counter cancer progression had been conceptualized much earlier, it was considered a fantasy until the seminal works of these scientists. In the mid 1990s, Dr. Allison’s research demonstrated that cytotoxic T-lymphocyte antigen 4 (CTLA-4), a receptor molecule expressed on T cells, acts as a brake to prevent immune response. CTLA-4 was originally identified by the French immunologists Pierre Golstein and colleagues in the late 1980s and it was hoped to be used to treat autoimmune diseases. However, Dr. Allison tested whether tumors could be targeted by immune cells by releasing the brakes applied by CTL-4. This led to the development of a monoclonal antibody against CTLA-4 that resulted in tumor regression in mice. The antibody Ipilimumab (trade name YervoyTM, Bristol-Myers Squibb, Princeton, NJ), was approved by the USFDA in 2011 for the successful treatment for advanced-stage melanoma.

On the other hand, in 1992, Dr. Honjo and coworkers discovered a new protein, Programmed Death 1 (PD-1) on T cells, another molecule that could act as a brake in the activation of the immune system by binding to PD-L1 on other cells. In fact, many cancers fooled the immune system by expressing PD-L1 on their surfaces. Blocking PD-1 with antibodies effectively reduced the size of tumors. This led to the development and approval of anti-PD-1 drugs like Keytruda (Merck & Co.) and Opdivo (Bristol-Myers Squibb) in 2014. Although met with initial skepticism over possible side effects, cancer immunotherapy has rapidly risen to the status of an effective therapeutic strategy against cancer in a short time making this award a well-deserved recognition for excellence in science.

References

  1. https://www.nobelprize.org/prizes/medicine/2018/press-release/
  2. https://www.sciencemag.org/news/2018/10/cancer-immunotherapy-pioneers-win-medicine-nobel

Note: Stay tuned to Geneonline for our special article on these Nobel laureates.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Mesoblast’s Resubmission Brings First-of-its-Kind Therapy One Step Closer to Approval
2023-03-09
Pfizer and GSK Neck and Neck for First FDA-Approved RSV Vaccine
2023-03-03
R&D
Latest Discovery in Metabolic Pathways of T-Cells Opens New Door to Immunology Research
2023-02-23
LATEST
GSK Bets $593 Million To License Scynexis’ Oral Antifungal
2023-03-31
3D Printed Brain Model Could Aid in Neurosurgery
2023-03-31
Latest Study on Neuronal Gene Expression May Shed Light on the Memory Formation Process
2023-03-30
Emergent BioSolutions’ Over-The-Counter Naloxone Nasal Spray Receives FDA Greenlight
2023-03-30
Current Trends of iPSC Manufacturing and Clinical Applications – An Interview with Professor Xianmin Zeng
2023-03-29
U.S.-German Joint Discovery May Spark Breakthrough in Diabetes Research
2023-03-29
Merck Regains Worldwide Rights to BAVENCIO After Parting Ways with Pfizer
2023-03-29
Scroll to Top